Nektar Therapeutics Downgraded by Zacks to Neutral (NKTR)

07-02-2014 Ticker ReportComments (0)

BiotechnologyNektar Therapeutics

Nektar Therapeutics logo Nektar Therapeutics (NASDAQ:NKTR) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research note issued to investors on Wednesday, Stock Ratings Network.com reports. They currently have a ...

Read more on Ticker Report

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top